Low dose (d1-5/7) oral etoposide regimen in intensively treated platinum-resistant epithelial ovarian cancer: The İzmir oncology group (IZOG) study . (2021). Annals of Medical Research, 27(1), 0029-0033. http://annalsmedres.org/index.php/aomr/article/view/591